To identify preoperative factors that predict 30-day mortality in patients undergoing simultaneous cardiac and renal surgery for urological tumours involving the peridiaphragmatic vena cava and right atrium-The ability to predict mortality and therefore avoid surgery in those patients likely to die would be valuable.
Introduction
Growth of renal cancer into the retro-hepatic inferior vena cava (IVC) and onwards into the right atrium presents a considerable circulatory and oncological challenge. Patients may be very short of breath due to the circulatory compromise; venous return may be reduced; right atrial function sub-optimal; embolism of tumour may further impair cardio-pulmonary function; there may be very marked swelling of the abdomen and lower limbs limiting mobility; the mass of tumour itself may be enormous; and metastasis at the time of presentation is common. Nevertheless, the situation is not hopeless and since the first reports of successful surgery in the 1970s [1, 2] there has been steady progress in our understanding of how best to manage the various challenges associated with intra-caval and intracardiac renal cancer. When the tumour is in the right atrium the combination of radical nephrectomy with intra-cardiac and retro-hepatic intravenous tumour extraction under conditions of hypothermic total circulatory arrest on cardiopulmonary bypass is one approach [3] [4] [5] [6] . However, there does continue to be debate about the necessity for hypothermic arrest and even bypass in these situations, particularly when the cephalad extent of venous invasion is supra-hepatic but not atrial [7] . Expert multidisciplinary intraoperative care from cardiothoracic surgeons, cardiothoracic anaesthetists, and urologists combined with postoperative intensive care allows the surgery to be performed with acceptable morbidity and mortality [8] . Nevertheless, this combination remains one of the highest risk procedures in urological surgery with contemporary series reporting 30-day mortality of~11% [6] .
Understanding which patients are most at risk of 30-day mortality would be a major step forward in the management of this condition. The surgery could then be offered selectively to those most likely to gain benefit from it. Other patients who were considered unlikely to survive the surgery or its aftermath might be better managed with drugs or palliative approaches. This would also mean that this very expensive care could be concentrated on those likely to derive benefit from it. The question of who to offer surgery to has been made more pertinent by the introduction of drugs that are active in renal cancer [9] . This is for two reasons viz, firstly, the drugs may be an alternative to surgery altogether; and secondly, the drugs make control of metastatic disease a possibility thus opening up the whole field of complex intracardiac surgery in more advanced oncological situations or even cytoreductive settings.
Abel et al. [6] in a recent multicentre collaborative review of outcomes from several centres in the USA highlighted performance status (PS) and serum albumin as key determinants of perioperative outcomes, although neither could absolutely discriminate between those destined to die from complications arising from surgery and those destined to do well. Other recent reports suggest that the surgical Apgar score [10] may help identify patients at high risk of complications after nephrectomy. The ideal test would be one that could be applied preoperatively and would be both highly sensitive and specific for predicting adverse perioperative outcomes.
In 2007, we established a programme in our hospitals for the management of these complex intra-cardiac renal tumours. Two urological surgeons, one cardiothoracic surgeon, and one cardiothoracic anaesthetist have been part of the core surgical team. Our approach since inception of the programme has been inclusive, i.e. to err on the side of offering surgery rather than selecting out only lower risk candidates, often because surgery seemed to represent a patient's only hope and because patients were often so symptomatic from the disease burden. In that time 46 patients have been referred to our team; 41 patients have undergone surgery, and only five patients have been managed in other ways. Now in 2016 we report the key lessons we have learned over that 8-year period regarding perioperative risk.
Patients and Methods
This study is a review of perioperative outcomes and 30-day mortality in all patients who have undergone simultaneous cardiac and renal tumour surgery between December 2007 and May 2015 at our centre. A full review of electronic and paper records was undertaken. All operative records had been filed prospectively.
The surgery was performed in the cardiothoracic units of St Thomas Hospital or London Bridge Hospital. The core team comprised two urological surgeons, one cardiothoracic surgeon, and one cardiothoracic anaesthetist. Patients underwent general anaesthesia; position was supine; incision median sternotomy with Mercedes Benz extension to the abdomen; early ligation of renal artery; full renal mobilisation; full mobilisation of right hepatic lobe; IVC mobilisation with division of caudate lobe branches; heparinisation, and establishment of cardiopulmonary bypass with cooling to 22°C and circulatory arrest for~20 min (if required); complete removal of tumour; IVC repair/grafting (if required); re-establishment of circulation; warming to 37°C; wound closure. Patients were admitted either to overnight theatre recovery or intensive care at the discretion of the team.
Potentially important pre-and perioperative variables were studied. These were then compared between patients who survived and patients who died in the perioperative period (30 days). Significance was determined using the Fisher's exact or Mann-Whitney U-test. As there were only three perioperative deaths, non-parametric logistic regression was used to identify which of these variables were statistically significantly associated with 30-day mortality. With respect to the international normalised ratio (INR), no further stratification or adjustments were made due to the occurrence of quasi-complete and complete separation.
Complications were categorised according to the ClavienDindo classification [11] . A secondary univariate analysis was performed to identify potential risk factors for serious complications (Clavien-Dindo Grade ≥III). Multivariate models were not possible due to the occurrence of quasicomplete and complete separation.
Results
In all, 46 patients were assessed and 41 (89%) underwent simultaneous urological and cardiac surgery. Five patients did not undergo surgery for the following reasons: one refused, three overwhelming metastatic load, and one extreme frailty.
Of the 41 operations, 34 (83%) were performed with curative intent in the absence of radiological evidence of metastases; seven (17%) were cytoreductive, and three (7%) patients died in the perioperative period. Histology confirmed: 35 clear cell RCC; two papillary RCC; one adrenocortical carcinoma; two primitive neuroectodermal tumours; and one leiomyosarcoma.
Operative details are outlined in Table 1 and postoperative complications are detailed by Clavien-Dindo classification in Table 2 . Overall, 30/41 (73%) patients had complications and 17 of these were Clavien-Dindo Grade ≥III, which included four returns to theatre for bleeding and one for gastric perforation, four patients developed pulmonary emboli in the postoperative period, and four developed fast atrial fibrillation.
Baseline characteristics of those that died and those that survived are compared in Table 3 . The INR, age and estimated GFR (eGFR) were the only preoperative variables that were statistically significantly associated with 30-day mortality. When conducting non-parametric logistic regression for INR (INR ≥1.5 vs <1.5) and perioperative death, we found an odds ratio (OR) of +∞ (95% CI: 4.04 to +∞) with a P value of 0.001. Even though the occurrence of quasi-complete separation did not allow us to estimate the actual OR or the upper limit of the 95% CI, the lower limit of 4.04 indicates a strong positive association between an INR ≥1.5 and risk of 30-day mortality. As a result, no further adjustments for age or eGFR could be made.
Despite preoperative correction of INR, all five patients who had raised preoperative INRs had serious complications (Clavien-Dindo Grade ≥III: one Grade IIIb, one Grade IVb, three Grade V), compared to 12/36 (33%) patients with a normal INR (P < 0.002; Table 2 ). The mortality rate for those with a raised INR ≥1.5 was three of five patients (60%) compared to 0/36 (0%) if the INR was normal. All three patients with a raised INR who died were aged ≥70 years. Of the eight patients aged ≥70 years, all five with a normal INR survived.
A similar non-parametric logistic regression model was conducted for serious complications as INR was the only risk factor showing an association in a multivariate analysis (Table 4) . When conducting a non-parametric logistic regression for INR (INR ≥1.5 and <1.5) and Clavien-Dindo Grade ≥III, we found an OR of +∞ (95% CI 1.51 to +∞), with a P value of 0.008. Even though the occurrence of quasicomplete separation did not allow us to estimate the actual OR or the upper limit of the 95% CI, the lower limit of 1.51 indicates a positive association between an INR ≥1.5 and risk of serious complications.
The positive predictive value (PPV) of raised INR alone for death was three of five patients (60%). The PPV of age ≥70 years was three of eight patients (37.5%). The PPV for the combination of age ≥70 years and INR ≥1.5 was three of three patients (100%). None of the 36 patients with a normal Table 1 Operative details (n = 41).
Variable Value
Cardiac bypass, n (%) 31 (76) Arrest + cooling, n (%) 27 (66) Blood loss, mL, median (range) 2250 (300-20 000) Operation time, h, median (range) 5 (2.25-7.5) Length of stay, days, median (range) 16 (7-97) compared to 36 mL/min/1.73 m 2 in those who died. All three patients who died had an eGFR of <40 mL/min/1.73 m 2 and overall the mortality in patients with an eGFR <40 mL/min/ 1.73 m 2 was three of eight patients (37.5%). Patients with a low GFR may be at increased risk of perioperative death. Constraints of time in the preoperative period precluded formal measurement of GFR (e.g. with chromium 51 labelled EDTA GFR) but might be of interest to investigate this association further.
The reason the INR becomes abnormal in these patients is likely to be complex but probably due to hepatocellular dysfunction arising as a consequence of congestion resulting from partial hepatic venous obstruction. This in turn leads to ischaemia of parenchymal cells and deranged production of clotting factors [12] . Alterations to coagulation parameters in these patients seem to be a sign of advancing liver disease. About 50% of our patients have abnormal preoperative liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP]), presumably indicating mild liver dysfunction, but only 12% of these patients had progressed to have an abnormal INR. It is also interesting that despite all the patients with abnormal preoperative coagulation having aggressive pre-procedure corrective measures with vitamin K and fresh frozen plasma infusions, major complications still transpired. The abnormalities signalled by a raised INR are probably far more complex than those simply of coagulation; and rather indicate [12, 13] . Only two of the five patients with an abnormal INR had a clinical Budd-Chiari syndrome as evidenced by ascites. None of the patients were jaundiced or encephalopathic.
Should patients with an abnormal INR not be offered this type of surgery? Based on the present study we would exercise caution if the patient is elderly, as all three patients who had a raised INR and were aged >70 years died (mortality 100%). In younger patients with an abnormal INR, we would still consider surgery if their background health was good prior to the tumour presentation, and particularly if the patient was very symptomatic from the circulatory disturbance; serious complications and a challenging postoperative period might be expected. Furthermore, our work should not be viewed in isolation. Abel et al. [6] suggested PS and serum albumin were also important factors associated with perioperative complications and 30-day mortality. In our present series, PS was not statistically significantly associated with 30-day mortality and deranged INR was a far more accurate predictor of mortality. We speculate that reverse causation might explain why PS is not significantly associated with death -rather than a reflection of underlying co-morbidity, poor PS may be a direct consequence of circulatory obstruction or tumour volume, and therefore reversible with surgical correction. It should also be noted that in the Abel et al. [6] series, albumin levels were only available on 50% of the patients making it difficult to be certain of the significance of the effect. A strength of our present study is that the INR was available on all our patients.
The present study is also very encouraging in demonstrating that combined cardiac and renal surgery can be performed in patients with a normal INR with a low risk of 30-day mortality. None of our 36 patients died. This may be valuable for optimising multidisciplinary clinical decision-making and for counselling patients before the procedure. Most patients despite feeling ill, having compromised circulation and dyspnoea on exertion, and a large volume of tumour can be steered through surgery successfully and have much to gain symptomatically from correction of the circulatory problem. Nonetheless, the surgical and anaesthetic challenges are considerable and success is only possible with a wellorganised highly committed skilful team. In the context of this disease this is also a high-volume team.
Despite overall 30-day mortality being low, complications are common in this group. Overall complications occurred in 30/ 41 (73%) with 17/41(42%) having Clavien-Dindo Grade ≥III complications. Even in the group we would now consider relatively low risk for perioperative death (normal INR, aged <70 years), the complication rate was still 20/31(64%). INR appears to be a risk factor for predicting serious complications (Clavien-Dindo Grade ≥III), as well as 30-day mortality.
This report is not considering the long-term oncological outcomes in this group of patients, but it is known that most patients with locally advanced renal cancer of this type will develop systemic relapse [14, 15] . The advent of multiple new medications for the control of metastatic disease does, however, offer hope to patients if their heavily symptomatic loco-regional disease can be controlled [16] . A particularly difficult scenario is to know whether this type of surgery should be offered in cytoreductive settings [17, 18] . A heavy burden of metastatic disease would in most instances disqualify a patient, but a low volume of metastatic disease in a younger patient, who has a normal INR and who is symptomatic from the circulatory disturbance, might be considered a reasonable candidate for cytoreductive surgery.
The main limitation of the present study is size, making it difficult to draw stronger conclusions. However, given the frequency of this tumour our single institution data is still clinically informative. Future study of the association between INR and 30-day mortality across wider groups of patients, and particularly in national audits of nephrectomy [19] would provide more events allowing for the calculation of multivariate logistic regression models. Moreover, our present data can now inform sample size calculations for these future studies.
In conclusion, in patients undergoing simultaneous renal and cardiac surgery for renal cancer, a raised preoperative INR appears to be a predictor of 30-day mortality in elderly patients (aged ≥70 years) and of significant postoperative complications in younger patients (aged <70 years). The surgery can be offered with more confidence to patients with a normal INR.
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